Pharmacological targeting of the protein synthesis mTOR/4E‐BP1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistanceCamille Duluc, Corinne Bousquet, Mounira Chalabi‐Dchar et al.|EMBO Molecular Medicine|2015Cited by 196
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16Mounira Chalabi‐Dchar, Corinne Bousquet, Marie‐Bernadette Delisle et al.|Gastroenterology|2015Cited by 46
Pharmacological targeting of the protein synthesis mTOR /4E‐ BP 1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistanceCamille Duluc, Corinne Bousquet, Mounira Chalabi‐Dchar et al.|HAL (Le Centre pour la Communication Scientifique Directe)|2015Cited by 13
Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer ImmunosuppressionMatteo Ponzo, Ilaria Cascone, Mounira Chalabi‐Dchar et al.|Cancers|2022Cited by 11
Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265Matteo Ponzo, Ilaria Cascone, Mounira Chalabi‐Dchar et al.|Cancers|2022Cited by 0